GE Healthcare invests in cardiac diagnostics
This article was originally published in The Gray Sheet
Executive Summary
Firm's "Healthymagination Fund" enters into a $5 million strategic alliance with CardioDx to co-develop diagnostics for cardiovascular disease, GE announces May 13. CardioDx's flagship product, Corus CAD, a non-invasive genomic test to assess the potential for coronary artery disease, launched in the U.S. last fall (1"The Gray Sheet" Sept. 7, 2009). The deal marks the $250 million Healthymagination Fund's first investment since its formation in October 2009 (2"The Gray Sheet" Nov. 2, 2009). The equity fund targets three broad areas for investment: diagnostics, health care information technology and life sciences
You may also be interested in...
CardioDx Launches Gene Test For Obstructive Coronary Disease
CardioDx is gradually rolling out its Corus CAD gene expression test, which quantifies the likelihood of obstructive coronary artery disease in patients with stable chest pain and no previous history of cardiac disease
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.